About Strand Therapeutics
Strand Therapeutics is a company based in Cambridge (United States) founded in 2017 by Tasuku Kitada. Strand Therapeutics has raised $103.14 million across 7 funding rounds from investors including Lilly, BeiGene and ARE. The company has 47 employees as of December 31, 2021. Strand Therapeutics offers products and services including Programmable mRNA Therapeutics and Self-Replicating mRNAs. Strand Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 47 as on 31 Dec, 2021
- Founders Tasuku Kitada
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Strand Therapeutics Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$103.14 M (USD)
in 7 rounds
-
Latest Funding Round
Not available
-
Investors
Lilly
& 11 more
-
Employee Count
47
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Strand Therapeutics
Strand Therapeutics offers a comprehensive portfolio of products and services, including Programmable mRNA Therapeutics and Self-Replicating mRNAs.
Creates mRNA with logic for targeted disease treatment
Develops replicating mRNA for long-acting medical effects
People of Strand Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Strand Therapeutics
Strand Therapeutics has successfully raised a total of $103.14M across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Strand Therapeutics
Strand Therapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, BeiGene and ARE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are provided to mission-driven founders by FPV Ventures.
|
Locked | Locked | Locked | |
|
Venture capital fund focused on tech startups
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Strand Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Strand Therapeutics
Investment portfolio details for Strand Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Strand Therapeutics
Detailed financials for Strand Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Strand Therapeutics Comparisons
Peer comparison for Strand Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Strand Therapeutics
Strand Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
Detailed competitors of Strand Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Strand Therapeutics
Complete news archive for Strand Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Strand Therapeutics
Strand Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Strand Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Strand Therapeutics is a funded company, having raised a total of $103.14M across 7 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Strand Therapeutics is 47.
Strand Therapeutics was founded in 2017 in Cambridge, United States. A programming platform is offered in the biotechnology sector to deliver mRNA therapeutics for multi-functional applications. Locations are detected and protein expression is enhanced in specific cell types within the patients body to support immunotherapy optimization. Services emphasize targeted treatments in oncology and related fields.
Strand Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Strand Therapeutics offers Programmable mRNA Therapeutics and Self-Replicating mRNAs.
Strand Therapeutics has 12 investors. Key investors include Lilly, BeiGene, ARE, HHS, and FPV Ventures.